Coromandel International Ltd: A Deep Dive into India's Agri Solutions Giant

Equity Research Report — June 2026

Company Overview

Coromandel International Ltd (NSE: COROMANDEL, BSE: 506395) is one of India's leading agri-solutions providers, operating at the intersection of crop nutrition, crop protection, and specialty nutrients. Part of the illustrious Murugappa Group, the company has built a formidable presence across the farming value chain over several decades. As of June 1, 2026, the stock trades at ₹1,788 per share, commanding a market capitalization of ₹52,698 crore.

The company's business is divided into two main segments: Nutrient and Other Allied Products (~85% of revenues) and Crop Protection (~15% of revenues). Coromandel is India's 2nd largest phosphatic fertilizer seller and the largest single super phosphate (SSP) seller with a market share of approximately ~15%. It holds a ~40% share in unique grade fertilizer sales in India and dominates the key markets of Andhra Pradesh and Telangana — India's largest complex-fertilizer markets.

Beyond fertilizers, the company is the 3rd largest manufacturer of mancozeb globally, with exports accounting for ~37% of crop protection revenues. Its biologicals division is a leading manufacturer of azadirachtin in the world with approximately ~65% export share, serving markets in the USA, Canada, and Europe.

Valuation Snapshot

The stock currently trades at a P/E of 26.3x, which is at a premium to peers like Chambal Fertilisers (9.58x) and Paradeep Phosphates (12.52x) but reflects the company's diversified business model, strong brand, and consistent profitability. The stock is down approximately ~34% from its 52-week high of ₹2,720, offering potential value for long-term investors.

Financial Performance: Profit & Loss Analysis

Quarterly Performance (Consolidated)

The September quarter is traditionally the strongest for Coromandel, driven by the Kharif cropping season. In Q2 FY26 (Sep 2025), the company reported its highest-ever quarterly sales of ₹9,654 crore, with operating profit of ₹1,147 crore and net profit of ₹793 crore (EPS of ₹27.31). However, Q4 FY26 (Mar 2026) was notably weak, with net profit declining to just ₹115 crore (EPS of ₹4.74), dragged by a 50% tax rate and softening demand.

Annual Financial Performance

FY26 revenue of ₹31,480 crore represents a massive ~31% year-on-year growth from ₹24,085 crore in FY25, marking the highest-ever annual sales. However, net profit of ₹1,898 crore was lower than FY25's ₹2,055 crore, indicating margin compression. Operating margins contracted to 10% in FY26 from 11% in FY25, while depreciation surged from ₹290 crore to ₹534 crore — a 84% increase reflecting heavy capital expenditure.

Growth Metrics

The 10-year sales CAGR of 11% and profit CAGR of 19% demonstrate the company's ability to compound earnings faster than revenue through operational efficiency. However, the 3-year profit CAGR of 0% highlights the earnings volatility in recent years, driven by commodity price swings and government subsidy dynamics. The stock has delivered a 23% CAGR over 10 years, significantly outperforming broader indices.

Balance Sheet Strength

Assets & Liabilities

The balance sheet has undergone significant transformation over the past decade. Fixed assets have ballooned from ₹1,380 crore in FY15 to ₹6,790 crore in FY26 — nearly 5x growth — reflecting the company's aggressive capacity expansion. Reserves have grown from ₹2,173 crore to ₹12,528 crore, indicating strong retained earnings.

Borrowings stood at ₹1,506 crore in FY26, up from ₹780 crore in FY25, as the company funded its expansion. However, the debt-to-equity ratio remains comfortable at approximately 0.12x, and the company had virtually zero net debt for several years between FY20-FY24. The total asset base has expanded to ₹24,503 crore, more than tripling from ₹8,362 crore a decade ago.

Investments surged to ₹2,044 crore in FY26 from ₹1,031 crore in FY25, suggesting the company is parking surplus funds or making strategic investments.

Cash Flow Analysis

Cash flow generation has been inconsistent but generally healthy. FY21 was an exceptional year with CFO of ₹4,150 crore (a CFO/Operating Profit ratio of 232%), driven by massive working capital release during the commodity supercycle. FY26 CFO of ₹1,558 crore was adequate but the CFO/OP ratio of 71% suggests working capital absorption. Free cash flow collapsed to just ₹22 crore in FY26, down dramatically from ₹2,030 crore in FY25, as the company invested heavily in fixed assets.

Key Financial Ratios

Debtor days have spiked from 19 days in FY25 to 49 days in FY26, a significant deterioration that warrants monitoring. This could indicate slower collections from government entities (fertilizer subsidies) or competitive pressures forcing relaxed credit terms. Inventory days also increased to 111 days from 98 days, suggesting potential inventory buildup.

ROCE has moderated from a peak of 38% in FY23 to 22.8% in FY26, largely due to the massive increase in the capital base from ongoing expansions. While still attractive in absolute terms, the declining trend reflects the capital-intensive nature of the growth investments.

The cash conversion cycle turned positive at 24 days in FY26 after being negative for two years, indicating less efficient working capital management.

Shareholding Pattern Analysis

Current Shareholding (Mar 2026)

Shareholding Trend (Key Periods)

The most striking trend is the surge in FII holdings from a mere 3.50% in FY20 to 13.02% in FY26 — nearly 4x increase in six years. This reflects growing international interest in India's agri-input sector and confidence in Coromandel's fundamentals. FII holding peaked at 14.51% in Sep 2025 before some profit-booking.

Promoter holding has gradually declined from 61.99% in FY17 to 56.35% in FY26, with the most recent quarter showing a 0.51% decrease. While still above 55%, this trend needs monitoring.

DII holdings stand at 18.19%, while retail/public holdings have compressed to 12.24% from 25.28% a decade ago, reflecting institutionalization of the shareholding.

Total shareholder count of 1,37,335 has more than doubled from 60,363 in FY17, indicating broadening retail participation.

Peer Comparison

Coromandel commands a premium valuation at 26.26x P/E compared to peers like Chambal (9.58x), Paradeep (12.52x), GSFC (9.68x), and RCF (17.41x). This premium is justified by:

• Superior ROCE of 22.75% — second only to Chambal's 25.51%
• Diversified business model spanning fertilizers, crop protection, and specialty nutrients
• Strong brand equity and distribution network
• Consistent dividend payments with a 0.67% yield

However, the Q4 FY26 quarter saw net profit decline of 42.51% — a concerning trend that contrasts with peers like Chambal (+29.84%) and RCF (+123.99%).

Strengths & Competitive Advantages

1. Market Leadership: Coromandel is the 2nd largest phosphatic fertilizer player and the largest SSP manufacturer in India with ~15% market share. Its ~40% share in unique grade fertilizers gives it pricing power in niche segments.

2. Diversified Revenue Streams: Unlike pure-play fertilizer companies, Coromandel derives ~15% of revenues from crop protection and has a growing biologicals business. This diversification reduces dependence on government subsidy policies.

3. Murugappa Group Backing: Part of the ₹74,000+ crore Murugappa Group, one of India's most respected conglomerates with a 125+ year legacy. The group's financial strength and governance standards provide a strong foundation.

4. Strong Distribution Network: The company has built an extensive distribution network across India, with particular strength in South and Western India. The brand Gromor is one of the most recognized fertilizer brands in the country.

5. Global Crop Protection Player: As the 3rd largest mancozeb manufacturer globally and leading azadirachtin producer with ~65% export share, the company has established international credibility.

6. Consistent Profitability: 10-year average ROE of 22% and ROCE of 23-26% demonstrate sustained profitability through commodity cycles.

Risks & Concerns

1. Government Policy Dependence: The fertilizer industry is heavily regulated, with subsidies comprising 50-70% of the final price of nutrients. Any change in subsidy policy, pricing formulas, or disbursement timelines can significantly impact cash flows and profitability.

2. Commodity Price Volatility: Phosphoric acid, ammonia, and sulphur prices directly impact margins. The company's inability to fully pass through raw material cost increases during periods of price volatility can compress margins.

3. Declining Promoter Holding: Promoter stake has dropped from 61.99% to 56.35% over the past decade, with a 0.51% decrease in the last quarter. While still comfortable, continued selling could signal reduced conviction.

4. Deteriorating Working Capital: Debtor days jumping from 19 to 49 and inventory days increasing to 111 suggest deteriorating working capital efficiency. This could pressure cash flows going forward.

5. Capital-Intensive Expansion: Fixed assets nearly doubled from ₹4,139 crore to ₹6,790 crore in a single year, while depreciation surged 84% from ₹290 crore to ₹534 crore. The returns on this incremental capital are yet to materialize fully.

6. Margin Compression: Operating margins have declined from 14% (FY21) to 10% (FY26), and the Q4 FY26 effective tax rate of 50% significantly eroded bottom-line performance.

Recent Developments & Outlook

FY26 Performance Highlights:

• Revenue hit an all-time high of ₹31,480 crore, up 31% YoY
• Operating profit grew 25% to ₹3,216 crore
• Net profit declined 7.6% to ₹1,898 crore due to higher depreciation and taxes
• EPS for FY26 stood at ₹66.31, down from ₹70.14 in FY25

Capacity Expansion: The company has been aggressively investing in expanding its fertilizer manufacturing capacity. Fixed assets grew from ₹4,139 crore to ₹6,790 crore in FY26 alone, suggesting significant capacity additions that should drive future revenue growth.

Crop Protection Growth: The crop protection segment continues to be a focus area, with the biologicals business offering higher margins and better growth prospects. The company's research pipeline of plant extract-based compounds and microbial bio-pesticides positions it well for the growing organic farming trend.

TTM Growth Momentum: Despite the weak Q4, TTM sales growth of 31% and TTM profit growth of 16% indicate underlying business momentum remains strong.

Valuation Assessment

At the current price of ₹1,788, Coromandel trades at:

• P/E of 26.3x on trailing earnings (FY26 EPS of ₹66.31)
• P/E of ~25.5x on FY25 earnings (EPS of ₹70.14)
• P/B of ~4.2x on book value of ₹426
• Dividend yield of 0.67%

The stock's 5-year average P/E has been in the 20-25x range, suggesting the current valuation is at the upper end of historical norms. However, considering the all-time high revenue and the potential for margin recovery as new capacities ramp up, the premium may be justified.

The 1-year return of -22% has brought the stock closer to fair value, and with the stock trading near its 52-week low of ₹1,720, contrarian investors may find the risk-reward increasingly attractive.

Investment Thesis

For Long-Term Investors: Coromandel International offers a compelling combination of market leadership in fertilizers, diversification into crop protection and biologicals, and strong corporate governance through the Murugappa Group. The 10-year stock price CAGR of 23% and consistent ROE of 17-22% make it a quality compounder. However, near-term headwinds from margin compression, elevated capex, and weak Q4 FY26 suggest patience may be rewarded with better entry points.

Key Catalysts:

• Normalization of tax rates from the 50% Q4 anomaly
• Commissioning of new capacities driving revenue growth
• Recovery in operating margins as scale benefits kick in
• Growth in high-margin crop protection and biologicals segments
• Government's continued focus on agricultural productivity

Key Risks to Monitor:

• Fertilizer subsidy policy changes
• Raw material price movements
• Working capital cycle deterioration
• Promoter holding trajectory

Conclusion

Coromandel International stands as a quality franchise in India's agricultural value chain. With ₹31,480 crore in FY26 revenues, a ₹52,698 crore market cap, ROCE of 22.8%, and ROE of 17%, it has the financial profile of a mature, well-run business. The recent 22% correction from 52-week highs has improved valuations, though the stock still trades at a premium P/E of 26.3x versus peers.

For investors with a 3-5 year horizon, Coromandel offers exposure to India's agricultural growth story through a diversified, well-governed company. The key is to monitor margin trends, working capital efficiency, and returns on incremental capital as the company's heavy capex cycle plays out. At current levels, the stock offers a reasonable entry point for patient, long-term investors seeking quality exposure to India's agri-input sector.